265 completed, 59 recruiting, 49 terminated, 49 unknown. 193 Phase 2, 96 Phase 1, 72 Not applicable, 28 Phase 3, 13 Phase 4.
Follow this condition Literature Review of Kidney Cancer trials Research Report on Kidney Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Treatment Delivery Preference In People With Kidney Cancer Nivolumab Injectable Product, Nivolumab, Pembrolizumab injection - Renal Cell Carcinoma, Kidney Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-09-24 | 2026-10-16 |
| The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy 18F-G1 - Solid Tumor Malignancies, Hematologic Cancer | Recruiting | Peking University First Hospital | 120 | 2026-09-08 | 2026-09-28 | |
| Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients. Experimental - Elderly, Breast Cancer | Phase 4 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 794 | 2026-09-01 | 2026-09-03 |
| Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer [64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma | Early Phase 1 | Not yet recruiting | Lumina Pharmaceuticals Inc | 40 | 2026-09-01 | 2026-08-28 |
| Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer Proteomic profiling of urinary EVs, Blood sample collection - Renal Cell Carcinoma, Clear-cell Renal Cell Carcinoma | Not yet recruiting | Mayo Clinic | 300 | 2026-07-15 | 2026-02-27 | |
| A Study of a Side Effects and Resource Navigation Program for People With Cancer Immunotherapy CARE Program - Kidney Cancer, Bladder Cancer | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 200 | 2026-06-09 | 2026-10-20 |
| Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors UDCA (Ursodeoxycholic acid), Placebo - Kidney Cancer | Phase 2 | Recruiting | Jinling Hospital, China | 162 | 2026-06-01 | 2026-10-15 |
| CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors Dose Level -1, Dose Level 1 (starting dose level), Dose Level 2 - Lymphoma, Myeloma | Phase 1 | Withdrawn | Baylor College of Medicine | 2026-06-01 | 2026-09-16 | |
| Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy nephrectomy - Kidney Cancer | Not applicable | Recruiting | Institut Paoli-Calmettes | 60 | 2026-05-13 | 2026-10-14 |
| A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) Nivolumab, HC-7366, ipilimumab - Phase 1b, HC-7366 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 35 | 2026-03-24 | 2026-09-25 |
| Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC Casdatifan, Zimberelimab - Renal Cell Carcinoma, Kidney Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2026-03-09 | 2026-03-20 |
| A Novel Haemostatic Agent for Robotic Partial Nephrectomy PuraBond - Kidney Cancer, Renal Cell Carcinoma | Not applicable | Withdrawn | The Royal Wolverhampton Hospitals NHS Trust | 2026-03-01 | 2026-03-13 | |
| Distance-Based Exercise to Preserve Function and Prevent Disability Exercise intervention, Telemedicine, Aerobic Exercise Intervention - Localized Malignant Solid Neoplasm, Anal Cancer | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 104 | 2026-02-11 | 2026-10-02 |
| EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors EBNK-001 + IL-15 + Pembrolizumab - Cancer, Sarcoma | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 83 | 2026-02-01 | 2026-02-18 |
| Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) Acarbose Tablets - Kidney Cancer | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2025-12-31 | 2026-02-17 | |
| Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients High intensity approach, Low intensity approach - Prostate Cancer, Kidney Cancer | Not applicable | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 90 | 2025-12-01 | 2026-09-03 |
| A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma Sasanlimab, Palbociclib, Axitinib - Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer | Phase 2 | Recruiting | Stephanie Berg | 25 | 2025-11-24 | 2026-08-20 |
| Tumor Rupture During Robotic Partial Nephrectomy robot-assisted partial nephrectomy - Kidney Cancer, Renal Neoplasms | Not yet recruiting | Azienda Ospedaliera Universitaria Integrata Verona | 100 | 2025-09-01 | 2025-07-15 | |
| 177LuPSMA in Renal Cell Carcinoma 177Lu-PSMA-617 - Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 24 | 2025-07-31 | 2026-02-24 |
| Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies. questionnaires - Prostate Cancer, Bladder Cancer | Completed | Istituto Oncologico Veneto IRCCS | 120 | 2025-06-18 | 2026-07-16 |
Showing 20 of 469. Sign in to see all of them.
Kidney Neoplasms (469) · Carcinoma, Renal Cell (262) · Breast Neoplasms (63) · Lung Neoplasms (63) · Prostatic Neoplasms (60) · Sarcoma (53) · Melanoma (52) · Urinary Bladder Neoplasms (51) · Ovarian Neoplasms (50) · Liver Neoplasms (47) · Pancreatic Neoplasms (43) · Head and Neck Neoplasms (42) · Colorectal Neoplasms (39) · Wilms Tumor (39) · Carcinoma, Non-Small-Cell Lung (37)
Female Urogenital Diseases (469) · Female Urogenital Diseases and Pregnancy Complications (469) · Male Urogenital Diseases (469) · Urogenital Diseases (469) · Neoplasms by Site (468) · Urologic Diseases (467) · Kidney Diseases (464) · Urogenital Neoplasms (464) · Urologic Neoplasms (464) · Neoplasms (441) · Neoplasms by Histologic Type (357) · Neoplasms, Glandular and Epithelial (309) · Carcinoma (277) · Adenocarcinoma (267) · Genital Diseases (99)
aldesleukin (34) · Sunitinib (23) · Interferon-alpha (21) · Cyclophosphamide (19) · Filgrastim (17) · Gene Expression Profiling (16) · Radiotherapy (16) · Peripheral Blood Stem Cell Transplantation (15) · Bevacizumab (14) · fludarabine phosphate (14) · Everolimus (12) · Gemcitabine (12) · Nivolumab (12) · Sorafenib (11) · Carboplatin (10)
Memorial Sloan Kettering Cancer Center (25) · National Cancer Institute (NCI) (21) · M.D. Anderson Cancer Center (16) · Children's Oncology Group (14) · National Institutes of Health Clinical Center (CC) (10) · Case Comprehensive Cancer Center (9) · Masonic Cancer Center, University of Minnesota (8) · Alliance for Clinical Trials in Oncology (7) · European Organisation for Research and Treatment of Cancer - EORTC (7) · Bristol-Myers Squibb (6) · Jonsson Comprehensive Cancer Center (6) · Northwestern University (6) · Dana-Farber Cancer Institute (5) · Eastern Cooperative Oncology Group (5) · SWOG Cancer Research Network (5)
United States (304) · France (34) · Canada (26) · United Kingdom (22) · Italy (18) · Netherlands (18) · China (13) · Australia (10) · Denmark (10) · Belgium (9) · Puerto Rico (8) · Switzerland (6) · Brazil (5) · Germany (5) · Russia (5)
Robert J. Motzer, MD (8) · Brian I. Rini, MD (5) · Eric Jonasch, MD (4) · John P. Hanson, MD (4) · Ronald M. Bukowski, MD (4) · Steven A. Rosenberg, MD, PhD (4) · W. Marston Linehan, M.D. (4) · Amado Zurita, MD (3) · Brian H. Kushner, MD (3) · Christopher W. Ryan, MD (3) · Nizar M. Tannir, MD (3) · Ralph Hauke, MD (3) · Richard L. White, MD (3)
PMID 19179301, PMID 21403127, PMID 22430088, PMID 23850254, PMID 25616710, PMID 31532520, PMID 37146227, PMID 41673778, PMID 10463285, PMID 10751849, PMID 10984562, PMID 11410496, PMID 11743264, PMID 12419754, PMID 12727829, PMID 12810695, PMID 14581348, PMID 15076283, PMID 15102658, PMID 15175957, PMID 15542800, PMID 15654272, PMID 15744595, PMID 15791454, PMID 15868587, PMID 15961764, PMID 16129848, PMID 16129869, PMID 16172460, PMID 16204015, PMID 16222691, PMID 16234526, PMID 16314647, PMID 16410127, PMID 16547940, PMID 16706633, PMID 16710034, PMID 16785067, PMID 16832603, PMID 16909426, PMID 16914576, PMID 16982775, PMID 17084075, PMID 17140723, PMID 17393073, PMID 17395103, PMID 17408850, PMID 17539021, PMID 17868728, PMID 17932908
P30CA043703 (12), U10CA031946 (4), U10CA032102 (4), P30CA008748 (3), P30CA022453 (3), P30CA072720 (3), P30CA012197 (2), P30CA016056 (2), P30CA033572 (2), P30CA036727 (2), P30CA060553 (2), U01CA062487 (2), 2015 (1), 2019 (1), 2025 (1)